Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duravelo-2: BT8009 monotherapy or combination therapy in advanced or metastatic urothelial cancer
2023-504231-41-01Phase 2Authorised
- Sponsor
- Bicycle Therapeutics
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 35
01
Overview
Phase 2, randomised, open-label trial of zelenectide pevedotin in transitional cell carcinoma (TCC), sponsored by Bicycle Therapeutics. Primary endpoints: Progression-free survival and Objective response rate. Planned start Sep 2024; status: authorised.
02
Drugs
zelenectide pevedotin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on 2023-504231-41-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504231-41-01.